David Piñeyro

TL;DR: The epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments, and the methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade.

TL;DR: Current understanding on the role of inosine in tRNAs, the enzymes that catalyze the modification and the evolutionary link between such enzymes and other deaminases are reviewed.

TL;DR: It is found that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine, which exhibits tumor-suppressor characteristics in vivo gliomas models and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress.

TL;DR: RNAseq is presented as a powerful tool to study post-transcriptional tRNA modifications at the precursor tRNA level and gives the first insights on the biology of I34 tRNA modification in metazoans.

TL;DR: Analysis of tumor biopsies from an unbiased cohort of 111 exceptional responder patients revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.